“But CBD, a cannabis compound also known as cannabidiol, exists in a gray area under federal law, and its exact legality has long been tricky to define. Any substance marketed as a supplement or food additive has to meet safety standards issued by the Food and Drug Administration, and that’s where things have gotten hairy for CBD manufacturers and marketers. Food and drinks that contain CBD have never actually been FDA-approved.
For years, the FDA hasn’t come down one way or another with guidance on how to regulate, label, or market CBD in supplements and food products. So store shelves proliferated with quasi-legal tinctures and gummies and beverages, all taking advantage of the FDA gray area. The FDA has warned companies selling CBD products and consumers about unproven health claims made by manufacturers, steadfastly holding that CBD doesn’t meet the definition of a dietary supplement — a position that has been challenged by the industry and consumers as demand for CBD has boomed. Without regulation, however, there’s no way for a consumer to know what, exactly, is in that CBD they bought at the gas station — or if it contains any CBD at all.
In late January, the agency finally issued a decision on CBD, and it’s a potentially damning blow to the industry. The FDA announced that it was denying three citizen petitions requesting guidance on CBD; the agency’s existing safety standards for supplements or food additives, it ruled, aren’t sufficient to regulate CBD’s use. Further, it expressed concerns that CBD products could be dangerous, especially with long-term use. Essentially, the FDA has said that CBD is a headache that it doesn’t want to deal with, so it’s kicking things over to Congress to sort out the mess.”
“The US policy does not take into account how entrenched the Israeli occupation of the West Bank and East Jerusalem has become. Israeli settlement growth in the West Bank has made a viable Palestinian state all but impossible. The US-led talks between Israel and the Palestine Liberation Organization have been on hiatus since President Barack Obama’s second term, and even at the time, there was little hope that they would amount to much. And Arab states like Morocco, UAE, and Bahrain have abandoned Palestinians, as they normalize relations with the State of Israel and eliminate any incentives for negotiations toward a Palestinian state.
Even establishment voices like former Ambassador Martin Indyk, who served as Obama’s Middle East envoy and is now a fellow of the Council on Foreign Relations, acknowledge that a one-state reality has set in.
To be fair, figuring out a new policy toward Israel and Palestine is no easy task. The US has come to be so dependent on Israel as a close security partner in the Middle East that it seemingly has overlooked its transgressions. Moreover, US politicians are reluctant to overhaul its approach and rankle influential domestic constituencies in the process.
But no good policy can rest on an outdated understanding of the facts on the ground. Clinging to a two-state solution that many leading Middle East experts do not view as workable is counterproductive and cedes US leadership. A commitment to a Palestinian state in name only cheapens and undermines its very possibility and boxes out the development of more practical policies that meet the moment. It leaves the US with few options in taking a leadership role in a place that’s central to US national interests and security.”
“if you thought mechanically that when wage growth is high and inflation is high, the only way these things go down is through higher unemployment — well you have to actually acknowledge now that maybe there is a wider set of possibilities.”
…
“Yeah, the idea that “no ‘help wanted’ sign should ever exist” is not to me a sign of a healthy economy. The story for much of 2021 was like, “Where have all the workers gone?” and the suggestion was that it must be that people don’t want to work. But in actuality, there were some sectors that were really eager to hire — Amazon expanding its warehousing staff probably did put pressure on other industries looking to hire. But competing sectoral demand for labor is just very different from saying people don’t want to work.”
“There are few better emblems of the failures of the US system of medical care than its inability to consistently provide insulin to Americans who need it.
The drug was discovered 100 years ago, and it provides essential and ongoing treatment for millions of people living with diabetes, one of the most common chronic diseases in the country. And yet one in six Americans with diabetes who use insulin say they ration their supply because of the cost. Some people end up spending nearly half of their disposable income on a medicine they must take to stay alive.
Though insulin generally costs less than $10 per dose to produce, some versions of the drug have a list price above $200. This is in part because, in the US, a warped market has allowed three companies to dominate the insulin business.”
…
“With California leading the way, a handful of states are considering trying to disrupt the market for essential medications, starting with insulin. The plan would be to manufacture and sell insulin themselves for a price that is roughly equivalent to the cost of production.”
…
“Medicare, the federal health insurance program for seniors, is about to institute a $35 per month cap on insulin costs for its beneficiaries, a provision of the Inflation Reduction Act that Democrats passed last year. But, because of the Senate’s arcane rules, they could not establish the same cap for private insurance, which covers more than half of Americans.”
…
“The main mechanism the US has for bringing down prescription drug prices is allowing generic drugs to compete with brand-name versions. When a company develops a new drug, it gets a period of exclusivity, 10 years or more, in which it is the only one able to make or sell that drug. But after that exclusivity period has passed, other companies can make a carbon copy and sell it at a lower price. Studies find that once several generic competitors come on the market, prices drop significantly.
But pharma companies are savvy about finding ways to extend their monopolies, with insulin and other drugs, by making minor tweaks to the chemical compound and asking for a patent extension. In the case of insulin, the companies can also modify the delivery device to protect their market share. Each product is meant to be used with specific, company-designed injectors. Though the patents on the artificial insulin developed in the 1990s have started expiring, these companies continue to hold and extend monopolies on either their devices or other chemical compounds, making it harder for generic competitors to enter the market.
Other federal regulations have added to the challenge. The FDA began to treat insulin as a biologic drug in 2020 — meaning it is made with living materials instead of combining chemicals like conventional pharmaceuticals — which comes with a different set of standards for generic versions, which are known as biosimilars, as well as manufacturing challenges given the precise conditions these products must be made in. Biosimilars can cost up to $250 million to produce and take up to eight years to bring to the market, versus a one-year investment of as little as $1 million for conventional generics. And unless the FDA recognizes a new generic insulin as interchangeable with the products already on the market, health insurers might not want to cover it and doctors may not be willing to prescribe it.
To add one more layer of difficulty, the current manufacturers can always decide to drop their prices to crowd out new generic competitors, given the gap between the retail price and the $10 cost of production. The first biosimilar drugs have come onto the market in the past few years, but only one of them has been deemed interchangeable with the brand-name version; ultimately, in late 2021, it was priced at only $20 less than the brand-name insulin it was competing with. More competition is needed to meaningfully depress prices.”
…
“If manufacturing a cheap generic insulin proves viable for California, the consequences could be enormous and stretch far beyond insulin. California would provide proof of concept, and a fledging public marketplace for public pharmaceutical production could potentially emerge.”
“A 2014 survey of economists found that nearly 20 percent of workers have noncompete clauses in their contracts. That number is more likely 50 percent for people in high-skilled and high-tech jobs”
…
“Marx added that these agreements don’t just specify that you can’t share a specific company’s secrets, but are often interpreted more broadly so that a person can’t use skills they had prior to working at that company — something he said can be debilitating to high-skilled workers and entrepreneurs.”
…
“Detractors of noncompete clauses say the agreements prohibit workers from getting jobs with competitors or even within the same industry. In doing so, they restrict job mobility and prevent workers from being able to push for higher wages, since changing jobs is often how workers get higher pay. These clauses can send them on lengthy job searches or even “career detours.””
…
“Pro-employer groups like the US Chamber of Commerce have argued that noncompete clauses can actually be pro-competitive because they protect an “employer’s special investment in, training of, and disclosure of sensitive business information to its employees.” In a statement released shortly after the FTC’s announcement, the organization called the rulemaking “blatantly unlawful” since it says the FTC doesn’t have the authority to promote the rule. “When appropriately used, noncompete agreements are an important tool in fostering innovation and preserving competition,” the Chamber said in an emailed statement.”
“Perhaps the greatest success of the American health care system these last few benighted years is this surprising fact: The uninsured rate has reached a historic low of about 8 percent.
That’s thanks in part to the pandemic — or, more precisely, the slew of emergency provisions that the government enacted in response to the Covid crisis.
One policy was likely the single largest factor. Over the past three years, under an emergency pandemic measure, states have stopped double-checking if people who are enrolled in Medicaid are still eligible for its coverage. If you were enrolled in Medicaid in March 2020, or if you became eligible at any point during the pandemic, you have remained eligible the entire time no matter what, even if your income later went up.
But in April, that will end — states will be re-checking every Medicaid enrollee’s eligibility, an enormous administrative undertaking that will put health insurance coverage for millions of Americans at risk.
The Biden administration estimates upward of 15 million people — one-sixth of the roughly 90 million Americans currently receiving Medicaid benefits — could lose coverage, a finding that independent analysts pretty much agree with. Those are coverage losses tantamount to a major economic downturn: By comparison, from 2007 to 2009, amid the worst economic downturn of most Americans’ lifetimes, an estimated 9 million Americans lost their insurance.”
“Balloons, it turns out, are already part of that US arsenal, with the Pentagon spending $3.8 billion over the past two years on them, according to Politico. As industry expert George Howell posted on LinkedIn, “High Altitude Balloons are actually a pretty smart thing to invest in, they’re cheap, easy to transport, can be fielded in large numbers and are payload agnostic,” meaning that while they’re most likely to be carrying cameras or radar, in certain situations balloons could field a weapon.”
“In Turkey and Syria, the high concentration of old, inflexible, concrete buildings, the lack of construction oversight, the Syrian civil war, and an ongoing cholera outbreak have left the region vulnerable to devastation. “You already had areas where people were displaced and living in temporary shelters,” said Traub. “In many ways, they’re already really compromised going into the disaster, and now they’re doubly displaced, and don’t have their support mechanisms.”
This is what happens when you end up on the wrong side of the disaster divide, which explains how unequal losses experienced by certain communities and countries following a natural disaster are chiefly due to the discrepancy of wealth and resources, limiting the ability to invest in the very things — strong buildings, weather prediction, rapid humanitarian response — that would prevent deaths. There’s a reason that 90 percent of disaster deaths between 1996 and 2015 occurred in low and middle-income nations, the United Nations Office for Disaster Risk Reduction found. It’s not that rich countries are somehow exempt from extreme weather and geological events. It’s that the lack of wealth, and everything it can buy, is what makes a quake or a hurricane or a tornado disastrous, more than the sheer strength of a storm or how high a quake scores on the Richter scale.”
“Turkey sits along two major fault lines, and after a deadly 1999 earthquake, the country passed stricter building codes, but they were not consistently enforced. And that goes beyond builders and contractors cutting corners or using inferior materials. There are also likely inspectors and municipal and state officials who issued permits when they shouldn’t have, or who looked the other way. There are those who lobbied for (and the politicians who backed) amnesty laws for buildings, essentially overriding ordinances in the name of quick construction and profit.
“Earthquakes are a natural phenomenon. Yes, it happens. But the consequences of the earthquake are quite, I would say, governmental and political and administrative,” said Hişyar Özsoy, a deputy chair of the Peoples’ Democratic Party and an opposition member of Parliament representing Diyarbakır, a city near the quake’s devastation.
All of this happened under the rule of President Recep Tayyip Erdoğan, who, along with his Justice and Development Party (AKP), has been in power for about two decades. Erdoğan made a construction boom the centerpiece of Turkey’s economic growth. At the same time, he has consolidated his power over institutions, the press, and the judiciary. This rapid economic growth, happening alongside democratic erosion, created layers of corruption and government mismanagement that allowed contractors to construct the buildings the way that they did.
“This is very much about the entire system that Erdoğan built — not just the politics of it, but also the economies behind it,” said Sebnem Gumuscu, a professor of political science at Middlebury College who has studied democracy and authoritarianism in Turkey. “The entire system is built around these corrupt networks, crony networks, and it is all levels: local level, national level, local branches of the party, local construction, developers — they’re all in this together.””
…
“Construction was also a source of political power for Erdoğan and the AKP, as major Turkish construction companies enriched themselves with government contracts and cozied up to the regime. That construction boom, which fueled other sectors of the economy, helped make Erdoğan and the AKP popular; that in turn allowed him to bolster his own authority, and helped put AKP into power at all levels of government, including state and municipal offices — often the ones tasked with overseeing permits or enforcing construction codes.
Politicians had incentives to approve things like amnesty laws. People enriched themselves through this ecosystem of cronyism, so there was no incentive to make sure earthquake-safe standards were applied. And the institutions that might hold these players and politicians accountable — the press, the civil service, the courts — were being hollowed out and eroded by Erdoğan’s increasingly authoritarian bent.
So, yes, developers and contractors likely were negligent, constructing buildings with cheap materials or designs that could not withstand a 7.8-magnitude quake. But these shortcuts couldn’t happen without the complicity or encouragement of government institutions, all of which knew the country’s vulnerabilities and pushed ahead anyway.”